• Miguel Ángel Barba-Romero, Joaquin Serena, Josep Maria Puig, Victor Valverde C, Vicente Climent, Jose Antonio Herrero, Rafael Huertas, and Roser Torra.
• Internal Medicine Department, Complejo Hospitalario y Universitario de Albacete, Castilla-La Mancha University, Albacete, Spain. Electronic address: mabarbar@sescam.jccm.es.
• Med Clin (Barc). 2019 Jul 19; 153 (2): 47-55.

Introduction And ObjectiveFabry disease (FD) is an X-linked lysosomal storage disorder due to a deficiency of the α-galactosidase A enzyme. Although women were historically considered only carriers, many studies have contradicted this fact. The main aim of this work was to set the first Spanish study out of the on-going registries on health status and management of women diagnosed with FD who were not receiving enzyme replacement therapy (ERT).Material And MethodsAn epidemiological, cross-sectional, descriptive and multicentre study was assessed in women diagnosed for FD who were not receiving ERT. Assessments on symptomatology and severity were collected using several clinical questionnaires. Additionally, clinical information and lab tests were obtained from clinical records.ResultsThirty-three women with a mean age of 45.6±16.2 years were studied. Symptom onset was at a median age of 35.5 years old (range: 30.0-51.5), being diagnosed a median of 2 years later (range: 1.0-1.5). Missense mutations were the most prevalent mutation (n=22, 68.8%). Although 69% considered themselves as asymptomatic, 22 (66.7%) showed at least one FD-related clinical symptom. Using Mainz Severity Score index and Fabry International Prognosis Index neurological symptomatology obtained higher scores both for severity and prognostic. The EQ-5D questionnaire showed 42.2% patients referring to some anxiety or depression, and 30.3% thought that their life was somehow altered by the pain. 62.5% were not receiving any treatment and ERT was offered only to one patient (3.6%) who refused it.ConclusionsAlthough most of the heterozygous women for FD had not received ERT or either symptomatic treatment, they present symptoms of disease. Careful follow-up of female patients or some adjuvant treatment may be considered to delay progressive organ damage and improve patient quality of life.Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

14 keywords...

hide…